A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma

References

• AkiyamaMHideshimaTHayashiTCytokines modulate telomerase activity in a human multiple myeloma cell lineCancer Res20026238768212097303
   PubMed Web of Science ®Google Scholar
• AndersonGGriesMKuriharaNThalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1Blood2006107309810516373662
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLFaconTSingle versus double autologous stem-cell transplantation for multiple myelomaN Engl J Med2003349249550214695409
   PubMed Web of Science ®Google Scholar
• BahlisNJMansoorALateganJCLenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4; 14) in multiple myeloma: MM016 TrialBlood20061081016a
   Web of Science ®Google Scholar
• BartlettJBDredgeKDalgleishAGThe evolution of thalidomide and its IMiD derivatives as anticancer agentsNat Rev Cancer200443142215057291
   PubMed Web of Science ®Google Scholar
• CarrascoDRTononGHuangYHigh-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patientsCancer Cell200693132516616336
   PubMed Web of Science ®Google Scholar
• CatleyLTaiYTShringarpureRProteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myelomaCancer Res20046487465315574786
   PubMed Web of Science ®Google Scholar
• ChauhanDCatleyLLiGA novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibCancer Cell200584071916286248
   PubMed Web of Science ®Google Scholar
• ChauhanDHideshimaTRosenSApaf-1/cytochrome c independent and Smac dependent induction of apoptosis in multiple myeloma cellsJ Biol Chem200127624453611356822
   PubMed Web of Science ®Google Scholar
• ChauhanDLiGHideshimaTBlockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341Oncogene200423359760215094775
   PubMed Web of Science ®Google Scholar
• ChauhanDUchiyamaHAkbaraliYMultiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kBBlood1996871104128562936
   PubMed Web of Science ®Google Scholar
• CorralLGHaslettPAJMullerGWDifferential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-αJ Immunol1999163380610384139
   PubMed Web of Science ®Google Scholar
• D’AmatoRJLoughmanMSFlynnEThalidomide is an inhibitor of angiogenesisProc Natl Acad Sci USA199491408257513432
   PubMed Web of Science ®Google Scholar
• DamianoJSCressAEHazlehurstLACell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell linesBlood19999316586710029595
   PubMed Web of Science ®Google Scholar
• DankbarBPadroTLeoRVascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myelomaBlood2000952630610753844
   PubMed Web of Science ®Google Scholar
• DaviesFERajeNHideshimaTThalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood2001982101611418482
   PubMed Web of Science ®Google Scholar
• DesikanRBarlogieBSawyerJResults of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalitiesBlood20009540081010845942
   PubMed Web of Science ®Google Scholar
• DredgeKHorsfallRRobinsonSPOrally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitroMicrovasc Res200569566315797261
   PubMed Web of Science ®Google Scholar
• FermandJ-PRavaudPChevretSHigh-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trialBlood199892313169787148
   PubMed Web of Science ®Google Scholar
• FonsecaRBarlogieBBatailleRGenetics and cytogenetics of multiple myeloma: a workshop reportCancer Res20046415465814989251
   PubMedGoogle Scholar
• FujitaJMestreJRZeldisJBThalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2Clin Cancer Res2001733495511705847
   PubMed Web of Science ®Google Scholar
• FujitaKAsamiYTanakaKAnti-angiogenic effects of thalidomide: expression of apoptosis-inducible active-caspase-3 in a three-dimensional collagen gel culture of aortaHistochem Cell Biol2004122273315221409
   PubMed Web of Science ®Google Scholar
• GregoryWMRichardsMAMalpasJSCombination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trialsJ Clin Oncol199210334421531068
   PubMed Web of Science ®Google Scholar
• Group MTsCCombination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trialsJ Clin Oncol1998163832429850028
   PubMed Web of Science ®Google Scholar
• HaslettPAHanekomWAMullerGThalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitroJ Infect Dis20031879465512660941
   PubMed Web of Science ®Google Scholar
• HayashiTHideshimaTAkiyamaMMolecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationBr J Haematol200512819220315638853
   PubMed Web of Science ®Google Scholar
• HideshimaTAndersonKCMolecular mechanisms of novel therapeutic approaches for multiple myelomaNat Rev Cancer200229273712459731
   PubMed Web of Science ®Google Scholar
• HideshimaTBergsagelPLKuehlWMAdvances in biology of multiple myeloma: clinical applicationsBlood20041046071815090448
   PubMed Web of Science ®Google Scholar
• HideshimaTCatleyLYasuiHPerifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cellsBlood200610740536216418332
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDRichardsonPNF-κB as a therapeutic target in multiple myelomaJ Biol Chem2002277166394711872748
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDShimaYThalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapyBlood20009629435011049970
   PubMed Web of Science ®Google Scholar
• HideshimaTNakamuraNChauhanDBiologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myelomaOncogene2001205991600011593406
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPAndersonKCNovel therapeutic approaches for multiple myelomaImmunol Rev20031941647612846814
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res2001613071611306489
   PubMed Web of Science ®Google Scholar
• KeiferJAGuttridgeDCAshburnerBPInhibition of NF-κB activity by thalidomide through suppression of IkappaB kinase activityJ Biol Chem200127622382711297551
   PubMed Web of Science ®Google Scholar
• KnopSGereckeCToppMSLenalidomide (Revlimid), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma -first results of a German multicenter phase I/II trialBlood2006108125a
   Web of Science ®Google Scholar
• KuehlWMBergsagelPLMultiple myeloma: evolving genetic events and host interactionsNat Rev Cancer200221758711990854
   PubMed Web of Science ®Google Scholar
• LeBlancRHideshimaTCatleyLPImmunomodulatory drug costimulates T cells via the B7-CD28 pathwayBlood200410317879014512311
   PubMed Web of Science ®Google Scholar
• LenhoffSHjorthMHolmbergEImpact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based studyBlood20009571110607678
   PubMed Web of Science ®Google Scholar
• LentzschSRogersMSLeBlancRS-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in miceCancer Res2002622300511956087
   PubMed Web of Science ®Google Scholar
• MassaiaMBorrionePBattaglioSIdiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapyBlood1999946738310397734
   PubMed Web of Science ®Google Scholar
• MitsiadesCSMitsiadesNMunshiNCFocus on multiple myelomaCancer Cell200464394415542427
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implicationsBlood20029945253012036884
   PubMed Web of Science ®Google Scholar
• MullerGWChenRHuangSYAmino-substituted thalidomide analogs: potent inhibitors of TNF-α productionBioorg Med Chem Lett1999916253010386948
   PubMed Web of Science ®Google Scholar
• RajeNKumarSHideshimaTCombination of the mTOR inhibitor Rapamycin and Revlimid (CC-5013) has synergistic activity in multiple myelomaBlood200410441889315319277
   PubMed Web of Science ®Google Scholar
• RajkumarSVJacobusSCallanderNA randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology GroupBlood2006b108239a
   Web of Science ®Google Scholar
• RajkumarSVBloodEVesoleDPhase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol2006a24431616365178
   PubMed Web of Science ®Google Scholar
• RajkumarSVHaymanSRLacyMQCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myelomaBlood20051064050316118317
   PubMed Web of Science ®Google Scholar
• RichardsonPJagannathSSchlossmanRA multi-center, randomized, phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens when used alone or in combination with dexameyhasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM)Blood2002100104a
   Web of Science ®Google Scholar
• RichardsonPGBloodEMitsiadesCSA randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaBlood200610834586416840727
   PubMed Web of Science ®Google Scholar
• RichardsonPGSchlossmanRLWellerEImmunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood20021003063712384400
   PubMed Web of Science ®Google Scholar
• RowlandTLMcHughSMDeightonJDifferential effect of thalidomide and dexamethasone on the transcription factor NF-κBInt Immunopharmacol20011496111367517
   PubMed Web of Science ®Google Scholar
• ShannonEAseffaAPankeyGThalidomide’s ability to augment the synthesis of IL-2 in vitro in HIV-infected patients is associated with the percentage of CD4+ cells in their bloodImmunopharmacology200046175910647875
   PubMed Web of Science ®Google Scholar
• SinghalSMehtaJDesikanRAntitumor activity of thalidomide in refractory multiple myelomaN Engl J Med199934115657110564685
   PubMed Web of Science ®Google Scholar
• StewartAKScangaSEZhuYXInhibition of Wnt pathway signaling by thalidomide and revlimid: studies in a drosophila model systemBlood2004104916a
   Web of Science ®Google Scholar
• TaiYTLiXFCatleyLImmunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implicationsCancer Res200565117122016357183
   PubMed Web of Science ®Google Scholar
• TerposEDimopoulosMASezerOThe effect of novel anti-myeloma agents on bone metabolism of patients with multiple myelomaLeukemia20072118758417611556
   PubMed Web of Science ®Google Scholar
• TsengSPakGWashenikKRediscovering thalidomide: a review of its mechanism of action, side effects, and potential usesJ Am Acad Dermatol199635969798959957
   PubMed Web of Science ®Google Scholar
• WeberDWangMChenCLenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal functionBlood20061081012a
   Web of Science ®Google Scholar
• WuASchefflerMRMulti-dose phamacokinetics and safety of CC-5013 in 15 multiple myeloma patientsJ Clin Oncol200422141s
   Web of Science ®Google Scholar